LEXX Lexaria Bioscience Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LEXX

Price (delayed)

$0.559

Market cap

$13.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$10.47M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 32

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's ...

Highlights
The EPS rose by 49% year-on-year and by 28% since the previous quarter
The net income has increased by 32% YoY and by 19% QoQ
The company's quick ratio has surged by 187% YoY but it has shrunk by 61% QoQ
LEXX's revenue has dropped by 69% year-on-year and by 47% since the previous quarter
The gross profit has plunged by 68% YoY and by 47% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexariabioscience.com
Peers: AMRN INVA TVRD CRBP

Key stats

What are the main financial stats of LEXX

LEXX stock price

How has the Lexaria Bioscience stock price performed over time
Intraday
-1.96%
1 week
-12.12%
1 month
2.19%
1 year
-44.65%
YTD
-9.4%
QTD
-0.18%

Financial performance

How have Lexaria Bioscience's revenue and profit performed over time
Revenue
$194,000
Gross profit
$194,000
Operating income
-$7.71M
Net income
-$7.73M
Gross margin
100%
Net margin
-3,985.6%
The net margin has dropped by 116% year-on-year and by 54% since the previous quarter
The operating margin has dropped by 115% year-on-year and by 54% since the previous quarter
LEXX's revenue has dropped by 69% year-on-year and by 47% since the previous quarter
The gross profit has plunged by 68% YoY and by 47% from the previous quarter

Price vs fundamentals

How does LEXX's price correlate with its fundamentals

Growth

What is Lexaria Bioscience's growth rate over time

Valuation

What is Lexaria Bioscience stock price valuation
P/E
N/A
P/B
2.92
P/S
71.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.96
The EPS rose by 49% year-on-year and by 28% since the previous quarter
LEXX's P/B is 29% below its last 4 quarters average of 4.1 and 17% below its 5-year quarterly average of 3.5
Lexaria Bioscience's equity has decreased by 28% from the previous quarter and by 15% YoY
LEXX's revenue has dropped by 69% year-on-year and by 47% since the previous quarter
The stock's price to sales (P/S) is 50% more than its last 4 quarters average of 47.6 and 20% more than its 5-year quarterly average of 59.4

Efficiency

How efficient is Lexaria Bioscience business performance
The return on sales has dropped by 115% year-on-year and by 54% since the previous quarter
The company's return on invested capital rose by 37% YoY and by 33% QoQ
Lexaria Bioscience's ROE has increased by 15% from the previous quarter but it has decreased by 8% YoY
Lexaria Bioscience's ROA has increased by 11% from the previous quarter but it has decreased by 8% YoY

Dividends

What is LEXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEXX.

Financial health

How did Lexaria Bioscience financials performed over time
The company's quick ratio has surged by 187% YoY but it has shrunk by 61% QoQ
LEXX's current ratio has surged by 172% year-on-year but it has dropped by 61% since the previous quarter
The debt is 98% smaller than the equity
LEXX's debt to equity has soared by 100% QoQ
Lexaria Bioscience's equity has decreased by 28% from the previous quarter and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.